相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L. J. Visseren et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)
Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication
Masato Furuhashi et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2022)
Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population
Hitoshi Hamamura et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
Jia Peng et al.
CARDIOVASCULAR DIABETOLOGY (2020)
The relationship between serum levels of LOX-1 ligand containing ApoAI as a novel marker of dysfunctional HDL and coronary artery calcification in middle-aged Japanese men
Aya Hirata et al.
ATHEROSCLEROSIS (2020)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy et al.
CIRCULATION (2019)
Inhibiting PCSK9-biology beyond LDL control
Robert M. Stoekenbroek et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lipid Lowering Therapy and Circulating PCSK9 Concentration
Tsuyoshi Nozue
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia
Yu Kataoka et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients
Stefan Toth et al.
CARDIOLOGY AND THERAPY (2017)
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
Rodrigo Alonso et al.
ATHEROSCLEROSIS (2016)
Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population
Hirotsugu Ueshima et al.
ATHEROSCLEROSIS (2016)
Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
Charalambos Vlachopoulos et al.
ATHEROSCLEROSIS (2016)
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
Karin Leander et al.
CIRCULATION (2016)
Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
Wuxiang Xie et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Comparison of Coronary Artery Calcium Presence, Carotid Plaque Presence, and Carotid Intima-Media Thickness for Cardiovascular Disease Prediction in the Multi-Ethnic Study of Atherosclerosis
Adam D. Gepner et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2015)
Removal of Plasma Mature and Furin-Cleaved Proprotein Convertase Subtilisin/Kexin 9 by Low-Density Lipoprotein-Apheresis in Familial Hypercholesterolemia: Development and Application of a New Assay for PCSK9
Mika Hori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
Daniel Gaudet et al.
AMERICAN JOURNAL OF CARDIOLOGY (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort
Afef Slimani et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2014)
Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
Michael J. Koren et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Carotid Intima-Media Thickness and Plaque in Apparently Healthy Japanese Individuals with an Estimated 10-Year Absolute Risk of CAD Death According to the Japan Atherosclerosis Society (JAS) Guidelines 2012: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA)
Aya Kadota et al.
Journal of Atherosclerosis and Thrombosis (2013)
Coronary Artery Calcification by Computed Tomography in Epidemiologic Research and Cardiovascular Disease Prevention
Akira Sekikawa et al.
JOURNAL OF EPIDEMIOLOGY (2012)
Relation Between Serum Total Cholesterol Level and Cardiovascular Disease Stratified by Sex and Age Group: A Pooled Analysis of 65 594 Individuals From 10 Cohort Studies in Japan
Sin-ya Nagasawa et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2012)
In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9
Rachid Essalmani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study
Stefania Lamon-Fava et al.
JOURNAL OF LIPID RESEARCH (2011)
Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels The Coronary Artery Risk Development in Young Adults Study
Chiang-Ching Huang et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
PCSK9: a convertase that coordinates LDL catabolism
Jay D. Horton et al.
JOURNAL OF LIPID RESEARCH (2009)
Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men - A cross-sectional study
Akira Sekikawa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Long-term prognosis associated with coronary calcification - Observations from a registry of 25,253 patients
Matthew J. Budoff et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post-World War II birth cohort
Akira Sekikawa et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A modified Poisson regression approach to prospective studies with binary data
GY Zou
AMERICAN JOURNAL OF EPIDEMIOLOGY (2004)
分享论文
